Cargando…
In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines
BACKGROUND: Invasive fungal infections such as candidiasis constitute an increasingly important medical problem. Drugs currently used for the treatment of candidiasis include polyenes (such as Amphotericin B) and azoles. Amphotericin B (AmpB) presents several limitations such as its nephrotoxicity a...
Autores principales: | Leon, Carlos G, Lee, Jinkyung, Bartlett, Karen, Gershkovich, Pavel, Wasan, Ellen K, Zhao, Jinying, Clement, John G, Wasan, Kishor M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173361/ https://www.ncbi.nlm.nih.gov/pubmed/21854638 http://dx.doi.org/10.1186/1476-511X-10-144 |
Ejemplares similares
-
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
por: Sivak, Olena, et al.
Publicado: (2011) -
A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model
por: Wasan, Ellen K., et al.
Publicado: (2010) -
Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis
por: Ibrahim, Fady, et al.
Publicado: (2013) -
ICOS Co-Stimulation: Friend or Foe?
por: Wikenheiser, Daniel J., et al.
Publicado: (2016) -
ICO investors
por: Fahlenbrach, Rüdiger, et al.
Publicado: (2020)